Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02922257 · ClinicalTrials.gov registry record
Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery
A clinical trial, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- 26
- Enrollment target
NCT02922257: Completed study, sponsored by Corcept Therapeutics.
NCT02922257 is a clinical trial that has completed, run by Corcept Therapeutics. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02922257 has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
Study Summary
This study will investigate the potential for FK506 binding protein 5 (FKBP5) (and other gene expression markers, for example pentraxin 3 \[PTX-3\], serum/glucocorticoid regulated kinase 1 \[SGK1\], and glycogen synthase kinase 3 beta \[GSK3b\]) to be developed as a biomarker for use in diagnosis of Cushing's syndrome, assessment of effectiveness of medical or surgical treatment, and detection of relapse of endogenous Cushing's syndrome after surgery.
Primary Outcome
Change in FKBP5 expression levels from baseline to after surgical treatment but prior to glucocorticoid replacement therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2016-11 |
| Est. Completion | 2018-10-30 |
What the finished NCT02922257 record still lists
NCT02922257 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02922257 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02922257 about?
NCT02922257 is a clinical study titled "Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery". This study will investigate the potential for FK506 binding protein 5 (FKBP5) (and other gene expression markers, for example pentraxin 3 \[PTX-3\], serum/glucocorticoid regulated kinase 1 \[SGK1\], and glycogen synthase kinase 3 beta \[GSK3b\]) to be developed as a biomarker for use in diagnosis of...
What is the current status of trial NCT02922257?
This trial is currently completed. The enrollment target is 26 participants. The study started on 2016-11. Estimated completion is 2018-10-30.
Who is sponsoring clinical trial NCT02922257?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia